Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Sponsor: Molecular Insight Pharmaceuticals, Inc.
ClinicalTrials ID:NCT02961491
This sub-study provides expanded access to AZEDRA for patients with iobenguane-avid metastatic/recurrent PPGL, focusing on safety data collection. Eligible participants must have a confirmed PPGL diagnosis, failed prior therapy, and meet specific health criteria. Participants receive a dosimetry dose and, if tumor avidity is confirmed, up to two therapeutic doses of AZEDRA.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The purpose of this sub-study is to provide expanded access of AZEDRA (Ultratrace Iobenguane I 131) and to evaluate the safety and tolerability of AZEDRA in subjects with iobenguane-avid malignant and/or recurrent pheochromocytoma/paraganglioma (PPGL).
Description
MIP-IB12B, the pivotal phase 2 study evaluating efficacy and safety of AZEDRA in patients with malignant relapsed/refractory PPGL, has completed its anticipated enrollment. The purpose of this sub-study, MIP-IB12B-EAP, is to provide expanded access to AZEDRA for newly enrolled subjects with iobenguane-avid metastatic and/or recurrent PPGL and to collect additional safety data.
Eligibility Criteria
Inclusion Criteria
- Able and willing to provide informed consent/assent and comply with protocol requirements
- Documented diagnosis of either pheochromocytoma or paraganglioma that was confirmed by histology or other supportive data (e.g. abnormal MIBG diagnostic study or elevated tumor markers)
- Ineligible for curative surgery for PPGL
- Failed a prior therapy for PPGL or have no alternative indicated therapy available
- Have definitive tumor avidity confirmed by the AZEDRA dosimetry dose
- Life expectancy of at least 6 months per physician
Exclusion Criteria
- Pregnant or nursing females
- Men or women of childbearing potential and unwilling to use a medically acceptable form of contraception from time of consent until 6 months following last therapeutic dose of AZEDRA
- Active CNS lesions by CT/MRI within 3 months of informed consent
- NYHA class IV heart failure, unstable angina pectoris or clinically significant cardiac arrhythmia that poses a risk of syncope or cardiac arrest
- Prior systemic radiotherapy resulting in marrow toxicity within 3 months of first AZEDRA therapeutic dose
- Prior iobenguane I 131 therapeutic exposure within 12 weeks of the first planned therapeutic dose
- Prior administration of whole-body radiation therapy within 12 weeks of the first planned therapeutic dose
- Prior external beam radiotherapy to > 25% of bone marrow
- Prior chemotherapy or investigational compound and/or device within 30 days of the dosimetry dose
- Other active malignancy requiring additional treatment except for superficial cutaneous neoplasms
- Karnofsky Performance Status < 60
- Clinically significant laboratory abnormalities prior to dosing as listed in the protocol (such as blood count abnormalities, liver enzyme abnormalities, and renal dysfunction)
- Medical history of AIDS/HIV+
- Active chronic alcohol abuse, chronic liver disease (not including liver metastases), hepatitis A, B, or C
- Known allergy to iobenguane that has required medical intervention
- Receiving a medication which inhibits tumor uptake of iobenguane I 131
- Any other condition, that in the opinion of the investigator, may compromise the safety or compliance of the subject
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| University of Iowa | 52242 | Iowa City | Iowa |
| Hospital of the University of Pennsylvania | 19104 | Philadelphia | Pennsylvania |
| MD Anderson Cancer Center | 77030 | Houston | Texas |
Get This Program In Your Inbox
You can sign up and apply your patients for this program.